Curr Rheumatol Rep. 2004 Oct;6(5):336-42.

Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis.

Source

Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow, G31 2ER, Scotland. i.b.mcinnes@clinmed.gla.ac.uk

Abstract

Targeting tumor necrosis factor-a has proven of considerable value in treatment for rheumatoid arthritis, with substantial benefits achieved in a proportion of treated patients. However, a significant number of patients do not achieve sufficient improvement and as a result there remains considerable unmet clinical need. A number of cytokines have recently been described with proinflammatory activity in rheumatoid arthritis synovitis, including interleukin (IL) -6, IL-12, IL-15, and IL-18. We review recent data that support the notion that some or all of these moieties offer therapeutic potential. The possibility that some may be useful in partial responders to tumor necrosis factor blocking agents or in synergy with the latter is discussed.

PMID:: 15355745; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Molecular Biology Databases

Etanercept - HSDB

Supplemental Content

Save items

Related citations in PubMed

Review Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis. [Curr Pain Headache Rep. 2005]
Review Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis.
McInnes IB, Gracie JA. Curr Pain Headache Rep. 2005 Dec; 9(6):405-11.
Review Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? [Annu Rev Immunol. 2001]
Review Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Feldmann M, Maini RN. Annu Rev Immunol. 2001; 19:163-96.
Review Cytokines in rheumatoid arthritis: trials and tribulations. [Mol Med Today. 2000]
Review Cytokines in rheumatoid arthritis: trials and tribulations.
Carteron NL. Mol Med Today. 2000 Aug; 6(8):315-23.
The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. [Rheumatology (Oxford). 2007]
The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
Nixon R, Bansback N, Brennan A. Rheumatology (Oxford). 2007 Jul; 46(7):1140-7. Epub 2007 May 3.
Review [Rheumatoid arthritis: current status of therapy]. [Tunis Med. 2007]
Review [Rheumatoid arthritis: current status of therapy].
El Bahri DM, Meddeb N, Sellami S. Tunis Med. 2007 Jan; 85(1):1-8.

See reviews... See all...

Cited by 4 PubMed Central articles

Review Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. [J Biomed Biotechnol. 2011]
Review Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.
Bolon B, Stolina M, King C, Middleton S, Gasser J, Zack D, Feige U. J Biomed Biotechnol. 2011; 2011:569068. Epub 2010 Dec 28.
Down-regulation of tristetraprolin expression results in enhanced IL-12 and MIP-2 production and reduced MIP-3alpha synthesis in activated macrophages. [Mediators Inflamm. 2006]
Down-regulation of tristetraprolin expression results in enhanced IL-12 and MIP-2 production and reduced MIP-3alpha synthesis in activated macrophages.
Jalonen U, Nieminen R, Vuolteenaho K, Kankaanranta H, Moilanen E. Mediators Inflamm. 2006; 2006(6):40691.
Review Gastrin-releasing peptide, substance P and cytokines in rheumatoid arthritis. [Arthritis Res Ther. 2005]
Review Gastrin-releasing peptide, substance P and cytokines in rheumatoid arthritis.
Green PG. Arthritis Res Ther. 2005; 7(3):111-3. Epub 2005 Mar 30.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheu...
Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis.
Curr Rheumatol Rep. 2004 Oct ;6(5):336-42.

PubMed
IgA antibodies against gliadin and gluten in multiple sclerosis.
IgA antibodies against gliadin and gluten in multiple sclerosis.
Acta Neurol Scand. 2004 Oct ;110(4):239-41.

PubMed
Genetic characterisation of Helicobacter pylori isolates from an Argentinean adu...
Genetic characterisation of Helicobacter pylori isolates from an Argentinean adult population based on cag pathogenicity island right-end motifs, lspA-glmM polymorphism and iceA and vacA genotypes.
Clin Microbiol Infect. 2004 Sep ;10(9):811-9.

PubMed
Evolutionary and mechanistic theories of aging.
Evolutionary and mechanistic theories of aging.
Annu Rev Entomol. 2005 ;50:421-45.

PubMed
Prion genetics: new rules for a new kind of gene.
Prion genetics: new rules for a new kind of gene.
Annu Rev Genet. 2004 ;38:681-707.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: